Lexicon Pharmaceuticals' (LXRX) Hold Rating Reiterated at Needham & Company LLC

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report)'s stock had its "hold" rating reaffirmed by investment analysts at Needham & Company LLC in a note issued to investors on Wednesday,Benzinga reports.

LXRX has been the topic of a number of other reports. Leerink Partners set a $6.00 price objective on Lexicon Pharmaceuticals and gave the stock an "outperform" rating in a report on Friday, October 18th. HC Wainwright reiterated a "buy" rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $5.00.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX traded down $0.00 during trading hours on Wednesday, reaching $0.82. The company had a trading volume of 2,946,477 shares, compared to its average volume of 5,808,694. The company has a market capitalization of $202.66 million, a price-to-earnings ratio of -1.10 and a beta of 1.06. Lexicon Pharmaceuticals has a 12-month low of $0.62 and a 12-month high of $3.73. The firm has a 50 day simple moving average of $0.79 and a 200-day simple moving average of $1.38. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The business had revenue of $1.75 million for the quarter, compared to analyst estimates of $3.14 million. During the same quarter in the previous year, the firm posted ($0.21) EPS. Research analysts expect that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its position in shares of Lexicon Pharmaceuticals by 71.2% during the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 13,246 shares during the period. SG Americas Securities LLC increased its position in shares of Lexicon Pharmaceuticals by 107.6% in the third quarter. SG Americas Securities LLC now owns 46,090 shares of the biopharmaceutical company's stock worth $72,000 after acquiring an additional 23,893 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Lexicon Pharmaceuticals by 40.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,957 shares of the biopharmaceutical company's stock valued at $84,000 after acquiring an additional 14,411 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Lexicon Pharmaceuticals by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 69,527 shares of the biopharmaceutical company's stock worth $109,000 after purchasing an additional 27,058 shares during the period. Finally, Intech Investment Management LLC purchased a new position in Lexicon Pharmaceuticals during the 3rd quarter worth approximately $115,000. Institutional investors own 74.70% of the company's stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.